RxDoctor Payments Data

Wesley Hoskyns, DO

Family Medicine · Cullman, ALNPI 1578192571

Payments from drug & device makers

$874in general payments, 2019–2025

Across 41 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$226
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$107
  • Sanofi-aventis U.S. LLC$96
  • Bayer$62
  • Novo Nordisk$53
  • Amgen$44
  • plus $286 from 11 others
$350in research payments, 2019–2025

Across 1 payment — averaging $350.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$350

What the payments were for

  • Food & beverage$874100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$874 in reported general payments places this provider in the 50th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$75,242
Medicare patients
179
Services billed
1,882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$74,855
JardianceEmpagliflozin34$39,225
MounjaroTirzepatide19$27,174
EliquisApixaban23$17,458
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,407
BelsomraSuvorexant21$9,571
FarxigaDapagliflozin Propanediol11$7,545
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,540
Testosterone Cypionate51$2,541
Telmisartan43$2,253
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,860
Atorvastatin Calcium132$1,718
Liothyronine Sodium25$1,493
Gabapentin74$1,111
Pantoprazole Sodium79$1,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$53$74,85567 claims
PfizerEliquis$31$17,45823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Cullman

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →